A multi-centre, open label study to investigate the recovery of IFN [interferon]-beta efficacy in relapsing-remitting multiple sclerosis patients with neutralising IFN-beta antibodies and reduced bioavailability.

Trial Profile

A multi-centre, open label study to investigate the recovery of IFN [interferon]-beta efficacy in relapsing-remitting multiple sclerosis patients with neutralising IFN-beta antibodies and reduced bioavailability.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Interferon beta-1a; Methylprednisolone
  • Indications Multiple sclerosis
  • Focus Biomarker; Pharmacodynamics; Pharmacokinetics
  • Acronyms RENeu
  • Sponsors Biogen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Aug 2011 Actual initiation date 12 Feb 2004 added as reported by Australian New Zealand Clinical Trials Registry.
    • 29 Aug 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top